AI app brings Parkinson’s tracking to your fingertips
12 September 2023
A new artificial intelligence tool has emerged that allows individuals with Parkinson's disease to assess the severity of their symptoms within minutes by simply tapping their fingers in front of a webcam.
Using the tool, participants tap their fingers 10 times in front of a webcam to assess motor performance on a scale of 0-4.
Doctors often have patients perform simple motor tasks to assess movement disorders and rate the severity using guidelines such as the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).
The new AI model provides a rapid assessment using the MDS-UPDRS guidelines, automatically generating computational metrics such as speed, amplitude, frequency, and period that are interpretable, standardised, repeatable, and consistent with medical guidebooks. It uses those attributes to classify the severity of tremors.
For the study, 250 global participants with Parkinson’s performed the finger-tapping task and the AI system’s ratings were compared with those of three neurologists and three primary care physicians.
While expert neurologists performed slightly better than the AI model, the AI model outperformed the primary care physicians with UPDRS certification.
“These findings could have huge implications for patients who have difficulty gaining access to neurologists, getting appointments, and travelling to the hospital,” says Ehsan Hoque, an Associate Professor at the University of Rochester and Co-Director of the Rochester Human-Computer Interaction Laboratory.
“It’s an example of how AI is being gradually introduced into healthcare to serve people outside of the clinic and improve health equity and access.”
The researchers say their method can be applied to other motor tasks, which opens the door to evaluating other types of movement disorders such as ataxia and Huntington’s disease.
The new Parkinson’s disease assessment is available online, though the researchers caution that it reflects an emerging technology and at this early stage should not be considered, on its own and without a physician’s input, as a definitive measure of the presence or severity of the disease.